Business
Change of Auditor
Change of Auditor.
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n\n23 August 2024\nN4 Pharma plc\n(\"N4 Pharma\" or the \"Company\")\n \nChange of Auditor\n \nN4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, announces that it has appointed Gravita II LLP as the Company's auditor.\n \nIn accordance with section 519 of the Companies Act 2006, the previous auditor, Saffery LLP, has deposited with the Company a statement confirming that there are no matters to be brought to the attention of the Company's members or creditors.\n \nFor more information please contact:\n \n\n\n\n\nN4 Pharma plc\nNigel Theobald, CEO\nLuke Cairns, Executive Director\n \nEngage with us directly at N4 Pharma Investor Hub\n \nTo hear more, visit\n\n\n \nVia N4 Pharma Investor Hub\n \n \nSign up at investors.n4pharma.com\n \n \n\n\n\n\nSP Angel Corporate Finance LLP\nNominated Adviser and Joint Broker\nMatthew Johnson/Caroline Rowe (Corporate Finance)\nVadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)\n\n\nTel: +44(0)20 3470 0470\n\n\n\n\nTurner Pope Investments (TPI) Limited\nJoint Broker\nAndy Thacker\nJames Pope\n\n\nTel: +44(0)20 3657 0050\n\n\n\n\n\n\n\n\n\n\n\n\n \n \nAbout N4 Pharma\nN4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec® and Liptide, a unique peptide/lipid delivery system via its subsidiary Nanogenics.\n \nN4 Pharma's business model is to partner with companies developing products in these fields to use Nuvec® or Liptide® as the delivery vehicle for these products. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.\n \nFor further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com.\n\n","length":5461,"tagName":"div"}]